Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
H5N1 vaccine
A H5N1 vaccine is an influenza vaccine intended to provide immunization to influenza A virus subtype H5N1.
Vaccination of poultry against the avian H5N1 influenza epizootic is widespread in certain countries. Some vaccines also exist for use in humans. As of July 2024, these include Aflunov, Audenz, Celldemic, and Incellipan.
The hemagglutinin protein is the main viral antigen of influenza A viruses, including the H5N1 subtype. Vaccination can induce antibodies that block the functions of the H5 hemagglutinin and neutralize virus infectivity.
The influenza virus is highly variable - the H5N1 virus infecting cattle in the USA is different from the viruses that showed up in poultry in 1997. However licensed vaccines can be updated in a process similar to that used for updating seasonal influenza vaccines.
February 2025, the Public Health Agency of Canada announced it had secured 500,000 initial doses of GSK's Arepanrix H5N1 human vaccine to protect people most at risk. This includes farmers, healthcare providers, and veterinarians. This vaccine incorporates antigenic material from the A/American wigeon/South Carolina/22-000345-001/2021 (H5N1)-like strain.
In December 2024 the UK government announced the purchase of five million doses of human H5 influenza vaccine to boost the country’s resilience in the event of a possible H5 influenza pandemic. The vaccine will be manufactured by CSL Seqirus UK Limited. The vaccine is based on the A/H5N8/Astrakhan/3212/2020 clade 2.3.4.4b strain of influenza. If needed, the H5 vaccine could be used while a pandemic-specific vaccine is developed and produced.
In July 2024, CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines.
In June 2024, the European Commission's Health Emergency Preparedness and Response Authority (HERA) signed a four-year contract with CSL Seqirus to secure 665,000 pre-pandemic vaccines with a provision for a further 40 million doses of avian flu vaccines. The member states participating in the contract are 15 of the 36 countries that have signed the EU's Joint Procurement Agreement for Medical Countermeasures, which includes all EU and EEA Member States. These fifteen countries are: Denmark, Latvia, France, Cyprus, Lithuania, Malta, the Netherlands, Austria, Portugal, Slovenia, Finland, Greece, Ireland, Iceland, and Norway.
Hub AI
H5N1 vaccine AI simulator
(@H5N1 vaccine_simulator)
H5N1 vaccine
A H5N1 vaccine is an influenza vaccine intended to provide immunization to influenza A virus subtype H5N1.
Vaccination of poultry against the avian H5N1 influenza epizootic is widespread in certain countries. Some vaccines also exist for use in humans. As of July 2024, these include Aflunov, Audenz, Celldemic, and Incellipan.
The hemagglutinin protein is the main viral antigen of influenza A viruses, including the H5N1 subtype. Vaccination can induce antibodies that block the functions of the H5 hemagglutinin and neutralize virus infectivity.
The influenza virus is highly variable - the H5N1 virus infecting cattle in the USA is different from the viruses that showed up in poultry in 1997. However licensed vaccines can be updated in a process similar to that used for updating seasonal influenza vaccines.
February 2025, the Public Health Agency of Canada announced it had secured 500,000 initial doses of GSK's Arepanrix H5N1 human vaccine to protect people most at risk. This includes farmers, healthcare providers, and veterinarians. This vaccine incorporates antigenic material from the A/American wigeon/South Carolina/22-000345-001/2021 (H5N1)-like strain.
In December 2024 the UK government announced the purchase of five million doses of human H5 influenza vaccine to boost the country’s resilience in the event of a possible H5 influenza pandemic. The vaccine will be manufactured by CSL Seqirus UK Limited. The vaccine is based on the A/H5N8/Astrakhan/3212/2020 clade 2.3.4.4b strain of influenza. If needed, the H5 vaccine could be used while a pandemic-specific vaccine is developed and produced.
In July 2024, CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines.
In June 2024, the European Commission's Health Emergency Preparedness and Response Authority (HERA) signed a four-year contract with CSL Seqirus to secure 665,000 pre-pandemic vaccines with a provision for a further 40 million doses of avian flu vaccines. The member states participating in the contract are 15 of the 36 countries that have signed the EU's Joint Procurement Agreement for Medical Countermeasures, which includes all EU and EEA Member States. These fifteen countries are: Denmark, Latvia, France, Cyprus, Lithuania, Malta, the Netherlands, Austria, Portugal, Slovenia, Finland, Greece, Ireland, Iceland, and Norway.